Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Urogen Pharma Ltd (URGN)

Urogen Pharma Ltd (URGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 994,691
  • Shares Outstanding, K 46,809
  • Annual Sales, $ 90,400 K
  • Annual Income, $ -126,870 K
  • EBIT $ -133 M
  • EBITDA $ -136 M
  • 60-Month Beta 1.29
  • Price/Sales 10.47
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 93.70% (+3.34%)
  • Historical Volatility 68.69%
  • IV Percentile 48%
  • IV Rank 9.41%
  • IV High 404.38% on 05/22/25
  • IV Low 61.45% on 08/26/25
  • Expected Move (DTE 5) 0.85 (4.00%)
  • Put/Call Vol Ratio 0.17
  • Today's Volume 422
  • Volume Avg (30-Day) 1,154
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 21,464
  • Open Int (30-Day) 22,206
  • Expected Range 20.40 to 22.10

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.65
  • Number of Estimates 3
  • High Estimate -0.52
  • Low Estimate -0.74
  • Prior Year -0.80
  • Growth Rate Est. (year over year) +18.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.99 +1.24%
on 01/05/26
24.71 -14.00%
on 12/16/25
-1.45 (-6.39%)
since 12/09/25
3-Month
15.86 +33.98%
on 10/10/25
30.00 -29.17%
on 11/26/25
+4.83 (+29.42%)
since 10/09/25
52-Week
3.42 +521.35%
on 05/21/25
30.00 -29.17%
on 11/26/25
+10.21 (+92.48%)
since 01/08/25

Most Recent Stories

More News
Permanent J Code for ZUSDURIâ„¢ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy

PRINCETON, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty...

URGN : 21.25 (-9.46%)
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J., Dec. 05, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty...

URGN : 21.25 (-9.46%)
UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference

PRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty...

URGN : 21.25 (-9.46%)
UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial

PRINCETON, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty...

URGN : 21.25 (-9.46%)
UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference

PRINCETON, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty...

URGN : 21.25 (-9.46%)
UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025

PRINCETON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty...

URGN : 21.25 (-9.46%)
Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURIâ„¢ Effective January 1, 2026

PRINCETON, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty...

URGN : 21.25 (-9.46%)
ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer

PRINCETON, N.J., Oct. 02, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company focused on developing and commercializing innovative solutions for urothelial and specialty cancers,...

URGN : 21.25 (-9.46%)
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty...

URGN : 21.25 (-9.46%)
UroGen Pharma to Present at Upcoming Investor Conferences

PRINCETON, N.J., Aug. 21, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty...

URGN : 21.25 (-9.46%)

Business Summary

UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company's product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen...

See More

Key Turning Points

3rd Resistance Point 26.09
2nd Resistance Point 25.10
1st Resistance Point 23.17
Last Price 21.25
1st Support Level 20.25
2nd Support Level 19.26
3rd Support Level 17.33

See More

52-Week High 30.00
Last Price 21.25
Fibonacci 61.8% 19.85
Fibonacci 50% 16.71
Fibonacci 38.2% 13.57
52-Week Low 3.42

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar